<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982549</url>
  </required_header>
  <id_info>
    <org_study_id>D4191L00116</org_study_id>
    <nct_id>NCT04982549</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC</brief_title>
  <official_title>A Prospective Study to Evaluate the Safety of Concurrent Durvalumab (MEDI4736) With Chemoradiation Therapy（CRT）Followed by Durvalumab for Chinese Unresectable Stage III Non Small Cell Lung Cancer（NSCLC）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single arm study assessing the efficacy and safety of&#xD;
      durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with&#xD;
      locally advanced, unresectable NSCLC (Stage III).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 35 patients with locally advanced, unresectable NSCLC (Stage III) who are&#xD;
      eligible to receive platinum-based CRT will be enrolled in and receive durvalumab + SoC CRT.&#xD;
      Patients with CR, partial response (PR), or stable disease (SD）based on Investigator&#xD;
      assessment at the 16-week tumor evaluation following completion of SoC CRT will continue to&#xD;
      receive durvalumab as consolidation treatment. Patients with RECIST 1.1-defined radiological&#xD;
      progressive disease (PD) will proceed to follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade ≥3 immune-mediated Adverse event</measure>
    <time_frame>From the date of first dose until disease progression,assessed up to 4 years</time_frame>
    <description>Grade ≥3 immune-mediated Adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of first dose until the date of objective disease progression or death,assessed up to 4 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the date of first dose until death due to any cause,assessed up to 4 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>From the date of first dose until the date of objective disease progression or death,assessed up to 4 years</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>From the date of first documented response (RECIST 1.1.) until the first date of documented progression or death in the absence of disease progression,assessed up to 4 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>From the date of first dose until 24 weeks.</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or distant metastasis(TTDM)</measure>
    <time_frame>From the date of first dose to until the first date of distant metastasis or death in the absence of distant metastasis,assessed up to 4 years</time_frame>
    <description>Time to death or distant metastasis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the date of enrollment until disease progression,assessed up to 4 years</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Unresectable Stage III NSCLC</condition>
  <arm_group>
    <arm_group_label>Durvalumab + platinum-based chemotherapy and radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:&#xD;
cisplatin/etoposide carboplatin/paclitaxel pemetrexed/cisplatin pemetrexed/carboplatin At the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab (intravenous infusion)</description>
    <arm_group_label>Durvalumab + platinum-based chemotherapy and radiation</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin/ Paclitaxel</intervention_name>
    <description>Carboplatin /Paclitaxel, as per standard of care</description>
    <arm_group_label>Durvalumab + platinum-based chemotherapy and radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed/ Cisplatin</intervention_name>
    <description>Pemetrexed / Cisplatin, as per standard of care</description>
    <arm_group_label>Durvalumab + platinum-based chemotherapy and radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed/ Carboplatin</intervention_name>
    <description>Pemetrexed / Carboplatin , as per standard of care</description>
    <arm_group_label>Durvalumab + platinum-based chemotherapy and radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)</description>
    <arm_group_label>Durvalumab + platinum-based chemotherapy and radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with histologically or cytologically-documented NSCLC&#xD;
&#xD;
          -  Locally advanced, unresectable (Stage III) NSCLC&#xD;
&#xD;
          -  World Health Organization (WHO) performance status 0-1&#xD;
&#xD;
          -  At least one measurable lesion, not previously irradiated&#xD;
&#xD;
          -  Must have a life expectancy of at least 12 weeks at randomization&#xD;
&#xD;
          -  Adequate lung function: Pre- or post-bronchodilator forced expiratory volume 1 of 1.0&#xD;
             L or &gt;40% predicted value and DLCO &gt;30% predicted value&#xD;
&#xD;
          -  Must provide an archived tumor tissue block(or at least 15 newly cut unstained&#xD;
             slides)≤3 years old; if archived sample unavailable then must provide a recent(≤3&#xD;
             months) tumor biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mixed small-cell and NSCLC histology&#xD;
&#xD;
          -  Receipt of prior or current cancer treatment, including but not limited to, radiation&#xD;
             therapy, investigational agents, chemotherapy, Durvalumab and mAbs.&#xD;
&#xD;
          -  Prior exposure to immune-mediated therapy, including but not limited to, other anti-&#xD;
             CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies.&#xD;
&#xD;
          -  Patients whose radiation treatment plans are likely to encompass a volume of whole&#xD;
             lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume&#xD;
&#xD;
          -  Planned radiation cardiac dose V50&gt;25%&#xD;
&#xD;
          -  Any medical contraindication of platinum-based doublet chemotherapy as listed in the&#xD;
             local labelling or known allergy/hypersensitivity to investigational product and/or&#xD;
             its excipients&#xD;
&#xD;
          -  History of the following: allogeneic organ transplantation, active or prior autoimmune&#xD;
             or inflammatory disorders, another primary malignancy, leptomeningeal carcinomatosis,&#xD;
             active primary immunodeficiency&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinming Yu, professor</last_name>
    <phone>15553181309</phone>
    <email>yujinming@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Feifei Teng, physician</last_name>
    <phone>13075305460</phone>
    <email>tengfeifei16@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming YU, professor</last_name>
      <phone>15553181309</phone>
      <email>yujinming@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Feifei Teng, physician</last_name>
      <phone>13075305460</phone>
      <email>tengfeifei16@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Yu, professor</last_name>
      <phone>15553181309</phone>
      <email>yujinming@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Feifei Teng, physician</last_name>
      <phone>13075305460</phone>
      <email>tengfeifei@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

